LFB S.A. Initiates Global Phase 3 Clinical Trial Of New Coagulation Factor Viia (Recombinant) In Patients With Hemophilia A And B
3/3/2014 9:17:36 AM
FRAMINGHAM, Mass.--(BUSINESS WIRE)--LFB SA, through its rEVO Biologics subsidiary, announced today initiation of the global Phase 3 program for LR769, a novel recombinant form of human Factor VIIa, in patients with congenital hemophilia A or B with inhibitors.
Help employers find you! Check out all the jobs and post your resume.
comments powered by